Dr Claire Madden-Smith and Dr Andy Jones Join CatSci as Board Advisors

Dec 20th 2022
Dr Claire Madden-Smith and Dr Andy Jones Join CatSci as Board Advisors

CatSci Ltd are thrilled to announce that Dr Claire Madden-Smith and Dr Andy Jones have joined the CatSci team as Advisors to the Board. Both Claire and Andy have extensive experience across the pharmaceutical landscape, and have both held numerous senior leadership roles that supported the growth of their organisations.  

Dr Claire Madden-Smith brings over 20 years of experience within the contract services sector. She completed her PhD, postdoctoral research, and consultancy work in material science and physical chemistry at Loughborough University. She then moved on to provide advanced solid-state analysis to the pharmaceutical industry at a start-up organisation. Over the following two decades, Claire was part of the continued growth and evolution of the company as an Executive Board Director, until its sale in 2013. She then became Senior Vice President of Juniper Pharma Services, where she led the rapid growth of their expanded contract development and manufacturing offering. She is a Non-Executive Director and Strategic Consultant to contract service organisations and private equity investors. Claire’s senior leadership experience and innovative approach to business development will facilitate CatSci’s ambitious growth plans.  

Dr Andy Jones has over 30 years’ experience in CMC (Chemistry, Manufacturing and Controls) development and pharma manufacturing services. He has been instrumental in leading the development, scale-up, and establishment of manufacturing processes for several blockbuster medicines. He has held many senior leadership positions in AstraZeneca, including Head of Manufacturing: Science and Technology, and Vice President for Pharmaceutical Innovation. He has recently concluded his role as Industrial Strategy Challenge Director in Medicines Manufacturing at Innovate UK, and consequently has a broad understanding of the exciting innovation happening in the global Pharma and Biotech manufacturing market. Andy’s experience in the CMC landscape will underpin our growth through supporting the expansion of our core capabilities and extension of our offerings into new emerging areas of advanced medicines manufacturing.  

Dr Claire Madden-Smith says:

I am thrilled to be joining CatSci as a Board Advisor, especially at such an exciting stage in their journey. I hope to bring my knowledge and experience of both the pharmaceutical industry and business evolution to aid CatSci on their mission to break down the silos in drug development to accelerate the delivery of life-changing medicines to patients in need. I am positive that we can continue the incredible growth path they have already embarked on in order to offer more and better to their customers all over the world.”  

Dr Andy Jones says:

It is great to be joining as a Board Advisor for CatSci as they continue to grow and evolve, constantly enhancing their capabilities to address the critical demands of the global pharmaceutical world. I am looking forward to utilising my experience in the CMC landscape, from large pharma companies to smaller innovative biotechs, and providing CatSci with invaluable insight to support their ambitious growth mission. Along with CatSci, I am passionate about the creation of new medicines to help patients in need, and I am excited by this partnership as together we can offer customers more and better to meet their dynamic portfolio needs.”  

 Dr Simon Tyler, our Chief Commercial Officer, says:

It’s an absolute privilege to add Claire and Andy to the CatSci team in newly created Board Advisory roles.  Bringing their substantial life sciences industry expertise, spanning drug (substance and product) development and manufacturing, and their experience across large pharma, emerging biopharma, external innovation, and government strategy, both Andy and Claire will be instrumental in shaping the growth trajectory of CatSci. I have no doubt that their contribution to the Board will be profound, and they will be integral in driving CatSci to become a more valuable partner for our customers and therefore better able to deliver on our singular purpose of getting new medicines into the hands of patients in need.”